Cerebras Lockup: 171M CBRS Shares Can Test a 34.5M IPO Float

Cerebras has already passed its first public-market test. CBRS priced at $185, survived a volatile debut, and closed September 25 at $206.63. The next test is less glamorous than a new AI model but just as important for the stock: how the market absorbs a much larger supply of shares becoming eligible for sale.

The company's IPO filing estimated that as many as 171.1 million shares could be released from lockup agreements or market-standoff provisions during the lockup period. Cerebras sold 34.5 million shares in its IPO, including the underwriters' full option. The potentially released pool is therefore almost five times the original public offering.

That does not mean 171.1 million shares will be dumped into the market. Eligibility to sell is not the same as an actual sale. It does mean CBRS investors should stop treating the original IPO float as a stable measure of supply.

The Cerebras lockup is a schedule, not one expiration date

Cerebras did not use a simple structure in which every insider waits 180 days and becomes free to sell on the same morning. Its IPO registration statement describes staged early releases, tax-related exceptions and a final lockup endpoint.

The main restriction ends at the earlier of two events:

• The second trading day after Cerebras releases results for the quarter ending September 30, 2026.
• The date 180 days after the final IPO prospectus.

Because the final prospectus was dated May 14, the 180-day alternative falls in November. A Q3 earnings release could trigger the main expiration first. The exact calendar day depends on when Cerebras reports and how trading days fall around that announcement.

Early-release provisions matter before then. The filing estimated that up to approximately 171.1 million shares could be released during the lockup period, including as many as 15 million held by directors and officers subject to Section 16 reporting. Separate exceptions permit limited sell-to-cover transactions for taxes when restricted stock units settle and allow some option holders to sell enough shares to cover exercise costs or tax obligations.

The design reduces the chance of one perfectly synchronized supply shock. It does not eliminate supply risk. It spreads that risk across several release windows and makes SEC ownership filings more useful than a single countdown clock.

Why 171.1 million shares changes the CBRS float calculation

Cerebras closed its IPO after selling 34.5 million Class A shares at $185 each. That figure included 4.5 million shares purchased through the underwriters' overallotment option. Trading began on Nasdaq on May 14.

The comparison is stark:

• IPO shares sold: 34.5 million.
• Estimated shares eligible for release during the lockup period: up to 171.1 million.
• Potential-release pool versus IPO offering: roughly 4.96 times larger.
• CBRS September 25 close: $206.63, about 11.7% above the IPO price.

At the September 25 close, 171.1 million shares carry a notional market value of about $35.4 billion. The original 34.5 million-share offering is worth roughly $7.1 billion at the same price. Those figures are scale markers, not forecasts of selling volume or capital flowing through the market.

The distinction matters because public float drives trading behavior. A stock with limited freely tradable supply can move sharply when demand rises. As restrictions expire, more holders gain the option to sell, borrow against shares or hedge. Even if only a fraction acts, the marginal supply can change volatility and the price investors are willing to pay.

TECHi's original Cerebras IPO guide explains the offering structure and listing. The lockup question deserves separate treatment because it asks something different: not whether Cerebras could complete the IPO, but whether post-IPO demand can absorb the next layers of ownership.

Form 4 and Form 144 filings are signals, not proof of a wave

Cerebras's investor-relations site lists several September ownership filings. A Form 4 filed September 4 reports a September 2 transaction involving director Susan Lior. Other September filings include Forms 4 and 144 from insiders.

A Form 4 reports changes in beneficial ownership by directors, officers or large shareholders. Form 144 generally provides notice of a proposed sale of restricted or control securities. Neither document proves that every eligible holder plans to sell, and a filing tied to an option exercise, conversion, gift, tax obligation or trading plan can have a different economic meaning from an open-market disposal made because an insider has lost confidence.

Investors should read each filing for transaction codes, footnotes, share counts and whether a Rule 10b5-1 plan was involved. Counting forms without reading them exaggerates the signal. Ignoring them misses the only public trail showing how newly available shares actually enter the market.

The useful measure is cumulative: how many shares move from restricted to transferable status, how many are sold, and whether daily trading volume expands enough to absorb them without a lasting discount.

Cerebras has operating evidence that can compete with new supply

Share supply is only half of the equation. Demand for CBRS depends on whether Cerebras continues converting its AI-inference claims into revenue and cash-generating capacity.

The company's second-quarter results provide the strongest current counterweight to the lockup risk. GAAP cloud and other services revenue rose 281% year over year to $126 million. Total GAAP revenue increased 74% to $180.1 million. Cerebras reported $8.6 billion of cash, restricted cash and short-term investments, plus $850 million of debt capacity.

Management also reported $25.4 billion in remaining performance obligations and more than 600 megawatts of data-center capacity live or under contract for delivery by the end of 2027. Full-year core revenue guidance was raised to $880 million to $890 million.

Those figures do not neutralize dilution or selling pressure. They explain why buyers may be willing to absorb it. A growing cloud business, large contracted backlog and substantial liquidity give Cerebras a fundamental case beyond scarcity. If operating milestones continue to improve, a larger float can make the stock easier for institutions to own without destroying the valuation.

The weak point remains profitability. Q2 GAAP gross margin was 14%, while core gross margin was 41% after excluding pass-through items and other adjustments. Core operating margin remained negative. The company is building data-center and manufacturing capacity ahead of revenue, so investors are underwriting both fast growth and a capital-intensive ramp.

TECHi's first-earnings analysis argued that customer quality and concentration mattered more than an early profit milestone. The lockup creates a related test: a wider shareholder base will demand evidence that the $25.4 billion obligation book turns into diversified, high-margin revenue rather than remaining concentrated in a few strategic relationships.

What could make the lockup bearish

The bearish setup needs more than shares becoming eligible. It needs available supply to outrun demand.

That could happen if insiders sell heavily into weak volume, if Q3 guidance disappoints, or if the market begins discounting the quality and timing of remaining performance obligations. A cluster of large Form 144 notices accompanied by open-market sales would be more meaningful than routine tax transactions.

Price also changes the incentive. CBRS at $206.63 is above the $185 IPO price, so many IPO buyers show a gain. Earlier employees and investors may have much lower cost bases. Some will diversify regardless of their view of the company. That is normal after an IPO, but normal selling can still pressure a stock when the newly eligible pool dwarfs the initial float.

The largest risk is interpretation. If the stock falls around a release date, investors may blame the lockup even when earnings, rates or the broader AI trade are responsible. Volume, ownership filings and company-specific news need to line up before supply receives the verdict.

What could make a larger CBRS float constructive

A larger float can improve market quality. More tradable shares may narrow spreads, increase institutional capacity and reduce the scarcity-driven jumps that make a young stock difficult to size. Index providers and large funds generally prefer liquidity.

Strong Q3 execution would help. If Cerebras meets its $214 million to $216 million core-revenue outlook, maintains progress toward its 2027 capacity plan and adds customers, new supply could meet a larger pool of fundamental buyers. The stock would then be judged more on revenue conversion and less on how few shares trade.

Product execution matters too. TECHi's analysis of the AMD–Cerebras disaggregated-inference claim showed that Cerebras is trying to make its low-latency architecture part of a broader AI stack rather than a standalone hardware novelty. Production deployments with AMD, AWS and OpenAI would give investors reasons to look through a technical lockup event.

The dates and evidence CBRS investors should track

There are four practical checkpoints:

• Q3 earnings date: this may determine the main lockup expiration under the earlier-of formula.
• Two trading days after Q3 results: the prospectus identifies this as one possible endpoint for the principal restriction.
• The 180-day anniversary of the May 14 prospectus: the alternative endpoint if it arrives first.
• Forms 4 and 144: these show reported ownership changes and proposed sales before and after the main expiration.

Investors should also compare daily volume with the number of shares disclosed in filings. A proposed or completed sale can sound large in isolation but have little market impact if normal volume is deep enough. The reverse is true when liquidity is thin.

Is CBRS stock a buy before the lockup expires?

The lockup is a valuation and liquidity risk, not a verdict on Cerebras's technology. The company has delivered strong cloud growth, raised guidance and assembled a large contracted revenue book. CBRS also trades above its IPO price, which gives restricted holders an incentive to realize gains.

At $206.63, the market is asking investors to accept both operating execution risk and a potential expansion in tradable supply. Buying before the main expiration is a bet that revenue growth and institutional demand can absorb shares as they become available. Waiting sacrifices the possibility of a pre-earnings rally but provides evidence on actual selling and Q3 performance.

The number to remember is not a predicted sale. It is the ratio: up to 171.1 million shares estimated for release during the lockup period against 34.5 million shares sold in the IPO. That nearly five-to-one difference is large enough to change how CBRS trades, even if most holders do nothing on the first day they are allowed to act.